📊 ARTV Key Takeaways
Is Artiva Biotherapeutics, Inc. (ARTV) a Good Investment?
Artiva Biotherapeutics is a pre-revenue clinical-stage biopharmaceutical company burning significant cash with no approved products or revenue generation. The company is consuming approximately $80M annually in free cash flow with only $26.7M in cash reserves, indicating a critical runway issue within 4-6 months without additional financing.
Artiva Biotherapeutics shows the classic high-risk profile of a pre-revenue clinical-stage biotech: no current revenue, deeply negative operating earnings, and heavy cash burn. The balance sheet is relatively clean with strong near-term liquidity and no meaningful debt, but the business currently depends on continued external funding unless it can materially reduce burn or generate partnership/product revenue. Fundamentals therefore point to weak operating quality despite adequate short-term financial health.
Why Buy Artiva Biotherapeutics, Inc. Stock? ARTV Key Strengths
- Strong balance sheet with minimal debt ($0M long-term debt) and debt-free capital structure
- Adequate liquidity position currently with 8.61x current ratio despite cash burn
- Recent insider activity with 7 Form 4 filings suggesting active leadership engagement
- Strong current liquidity with a current and quick ratio of 8.61x
- Debt-free balance sheet with low financial leverage
- Large equity base relative to liabilities provides some balance sheet cushion
ARTV Stock Risks: Artiva Biotherapeutics, Inc. Investment Risks
- Zero revenue with 100% YoY revenue decline - no commercial progress or approved products
- Severe cash burn of $76.8M in operating cash flow and $79.3M negative free cash flow annually
- Critical cash runway crisis - only $26.7M cash reserves against $79.3M annual burn rate creates existential dilution risk within months
- Massive shareholder value destruction with -76.3% ROE and -64.0% ROA
- Operating losses of $89.8M indicate no clear path to profitability or commercialization success
- No revenue base, making growth quality and business model validation unproven
- High operating and free cash flow losses indicate substantial ongoing cash burn
- Negative ROE and ROA reflect weak capital efficiency and continued dependence on financing
Key Metrics to Watch
- Cash balance and runway to next milestone/financing event
- Clinical trial progress and regulatory pathway milestones
- Monthly cash burn rate and operating cash flow trends
- Capital raise announcements and dilution per share
- Operating expense reduction initiatives
- Quarterly operating cash burn relative to cash and equivalents
- Any emergence of recurring revenue or collaboration/milestone income that improves earnings quality
Artiva Biotherapeutics, Inc. (ARTV) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 8.61x current ratio provides a solid financial cushion.
ARTV Profit Margin, ROE & Profitability Analysis
ARTV vs Healthcare Sector: How Artiva Biotherapeutics, Inc. Compares
How Artiva Biotherapeutics, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Artiva Biotherapeutics, Inc. Stock Overvalued? ARTV Valuation Analysis 2026
Based on fundamental analysis, Artiva Biotherapeutics, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Artiva Biotherapeutics, Inc. Balance Sheet: ARTV Debt, Cash & Liquidity
ARTV Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Artiva Biotherapeutics, Inc.'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-5.81 indicates the company is currently unprofitable.
ARTV Revenue Growth, EPS Growth & YoY Performance
ARTV Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2024 | $26.7M | $11.3M | $-0.92 |
| Q2 2024 | $3.5M | -$11.3M | $-14.09 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Artiva Biotherapeutics, Inc. Dividends, Buybacks & Capital Allocation
ARTV SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Artiva Biotherapeutics, Inc. (CIK: 0001817241)
📋 Recent SEC Filings
❓ Frequently Asked Questions about ARTV
What is the AI rating for ARTV?
Artiva Biotherapeutics, Inc. (ARTV) has a Combined AI Rating of SELL from Claude (STRONG SELL) and ChatGPT (SELL) with 88% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are ARTV's key strengths?
Claude: Strong balance sheet with minimal debt ($0M long-term debt) and debt-free capital structure. Adequate liquidity position currently with 8.61x current ratio despite cash burn. ChatGPT: Strong current liquidity with a current and quick ratio of 8.61x. Debt-free balance sheet with low financial leverage.
What are the risks of investing in ARTV?
Claude: Zero revenue with 100% YoY revenue decline - no commercial progress or approved products. Severe cash burn of $76.8M in operating cash flow and $79.3M negative free cash flow annually. ChatGPT: No revenue base, making growth quality and business model validation unproven. High operating and free cash flow losses indicate substantial ongoing cash burn.
What is ARTV's revenue and growth?
Artiva Biotherapeutics, Inc. reported revenue of $0.0.
Does ARTV pay dividends?
Artiva Biotherapeutics, Inc. does not currently pay dividends.
Where can I find ARTV SEC filings?
Official SEC filings for Artiva Biotherapeutics, Inc. (CIK: 0001817241) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is ARTV's EPS?
Artiva Biotherapeutics, Inc. has a diluted EPS of $-3.43.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is ARTV a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Artiva Biotherapeutics, Inc. has a SELL rating with 88% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is ARTV stock overvalued or undervalued?
Valuation metrics for ARTV: ROE of -76.3% (sector avg: 15%), net margin of N/A (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy ARTV stock in 2026?
Our dual AI analysis gives Artiva Biotherapeutics, Inc. a combined SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is ARTV's free cash flow?
Artiva Biotherapeutics, Inc.'s operating cash flow is $-76.8M, with capital expenditures of $2.6M.
How does ARTV compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin N/A (avg: 12%), ROE -76.3% (avg: 15%), current ratio 8.61 (avg: 2).